AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|AAPL343.46+1.46 (+0.43%) ▲|ABBV285.42+2.02 (+0.71%) ▲|ABT104.89+0.21 (+0.20%) ▲|ACN229.68+4.76 (+2.12%) ▲|ADBE245.20-6.47 (-2.57%) ▼|AMAT409.29-20.72 (-4.82%) ▼|AMD528.75-33.48 (-5.95%) ▼|AMGN432.49-1.54 (-0.35%) ▼|AMT185.27+3.91 (+2.16%) ▲|AMZN250.00-4.76 (-1.87%) ▼|AVGO328.75-15.58 (-4.52%) ▼|AXP313.59-0.28 (-0.09%) ▼|BA190.21+1.48 (+0.78%) ▲|BAC51.23-0.47 (-0.91%) ▼|BKNG163.45-2.35 (-1.42%) ▼|BLK1,134.38+13.60 (+1.21%) ▲|BMY59.75-0.82 (-1.35%) ▼|BNY143.30+1.21 (+0.85%) ▲|BRK-B532.02+6.34 (+1.21%) ▲|C124.26+1.05 (+0.85%) ▲|CAT730.76-4.88 (-0.66%) ▼|CL94.11+1.44 (+1.55%) ▲|CMCSA21.90+0.13 (+0.60%) ▲|COF201.74+2.88 (+1.45%) ▲|COP146.51+4.78 (+3.37%) ▲|COST989.11+11.10 (+1.14%) ▲|CRM240.70-6.04 (-2.45%) ▼|CSCO107.39-2.46 (-2.24%) ▼|CVS92.36-0.22 (-0.24%) ▼|CVX224.99+5.67 (+2.59%) ▲|DE641.86-8.81 (-1.35%) ▼|DHR229.04-2.46 (-1.06%) ▼|DIS110.59-0.09 (-0.08%) ▼|DUK121.47+2.59 (+2.18%) ▲|EMR161.47-0.68 (-0.42%) ▼|FDX293.55-1.99 (-0.67%) ▼|GD344.23+7.20 (+2.14%) ▲|GE313.83+1.83 (+0.59%) ▲|GEV921.20-5.24 (-0.57%) ▼|GILD156.19-1.18 (-0.75%) ▼|GM83.96+0.30 (+0.36%) ▲|GOOG336.91-8.00 (-2.32%) ▼|GOOGL340.59-8.63 (-2.47%) ▼|GS881.26-10.02 (-1.12%) ▼|HD309.63+1.39 (+0.45%) ▲|HON211.41+0.91 (+0.43%) ▲|IBM232.14-1.98 (-0.85%) ▼|INTC89.85-5.52 (-5.79%) ▼|INTU325.15-5.02 (-1.52%) ▼|ISRG426.70-1.16 (-0.27%) ▼|JNJ255.56+2.28 (+0.90%) ▲|JPM339.72+4.19 (+1.25%) ▲|KO93.90+1.90 (+2.07%) ▲|LIN498.43+5.21 (+1.06%) ▲|LLY1,257.03+5.42 (+0.43%) ▲|LMT552.09+19.45 (+3.65%) ▲|LOW197.38+1.66 (+0.85%) ▲|LRCX263.94-13.52 (-4.87%) ▼|MA617.42+1.10 (+0.18%) ▲|MCD242.97+0.47 (+0.19%) ▲|MDLZ63.91+0.88 (+1.40%) ▲|MDT94.75-0.70 (-0.73%) ▼|META709.33-27.40 (-3.72%) ▼|MMM164.75-0.58 (-0.35%) ▼|MO75.11+1.27 (+1.72%) ▲|MRK145.95+0.76 (+0.52%) ▲|MS180.57-1.53 (-0.84%) ▼|MSFT529.05-10.39 (-1.93%) ▼|MU878.84-52.40 (-5.63%) ▼|NEE79.80+0.84 (+1.06%) ▲|NFLX70.53-2.08 (-2.86%) ▼|NKE37.13-0.01 (-0.03%) ▼|NOW141.97-6.60 (-4.44%) ▼|NVDA214.13-3.10 (-1.43%) ▼|ORCL128.23-6.24 (-4.64%) ▼|PEP131.49+3.11 (+2.42%) ▲|PFE29.58+0.14 (+0.48%) ▲|PG159.35+2.27 (+1.45%) ▲|PLTR186.03-14.47 (-7.22%) ▼|PM205.20+5.30 (+2.65%) ▲|QCOM172.11-6.29 (-3.53%) ▼|RTX193.92+6.97 (+3.73%) ▲|SBUX97.52+0.64 (+0.66%) ▲|SCHW91.96-2.20 (-2.34%) ▼|SO91.18+2.00 (+2.24%) ▲|SPG205.44+2.05 (+1.01%) ▲|T23.44-0.06 (-0.26%) ▼|TMO690.00-6.49 (-0.93%) ▼|TMUS159.10+2.07 (+1.32%) ▲|TSLA354.72-7.72 (-2.13%) ▼|TXN276.48-2.64 (-0.95%) ▼|UBER70.35-0.92 (-1.29%) ▼|UNH401.43-5.24 (-1.29%) ▼|UNP289.04+0.33 (+0.11%) ▲|UPS97.48-0.35 (-0.36%) ▼|USB58.73+1.34 (+2.33%) ▲|V402.61+2.86 (+0.72%) ▲|VZ44.79+0.39 (+0.88%) ▲|WFC83.87+1.12 (+1.35%) ▲|WMT118.81+0.94 (+0.80%) ▲|XOM178.98+4.30 (+2.46%) ▲|
11.9 C
New York
Saturday, October 17, 2026

Tag: receptor

newssourceFORcompanycontentinformation1releasesmarket

Finding Suggests Treatment Approach for Autoimmune Diseases

NEW YORK, June 30, 2025 /PRNewswire/ -- An engineered protein turns off the kind of immune cells most likely to damage tissue as part...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy

CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure.

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line...

— Approval based on Phase III SACHI Trial results which showed a 66% reduced risk of progression or death as compared to platinum-based chemotherapy —

Theranos Makes a Big Bang at the FDA

PALM BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- Today marks a significant milestone for theranos and its diagnostic technology. The theranos system performs automated sample processing and analysis to produce clinical test results. The U.S. Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) has affirmed that the core technology is not under question.

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host a virtual nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 at 8:00 AM ET. For English speakers, please click here to register. For individuals preferring instant Chinese translation, please click here.

STORM Therapeutics Appoints Veteran Cancer Drug Developer Dr. Eric Martin as Chief Development Officer

CAMBRIDGE, England, June 26, 2025 /PRNewswire/ -- STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today...

Mind Vault Introduces Senior Cognitive Health Update: Brain Support Formula Highlights Age-Focused Innovation

Cognitive Wellness Announcement Highlights New Senior Brain Health Formulation with Scientifically Backed Ingredients 
Cognitive Wellness Announcement Highlights New Senior Brain Health Formulation with Scientifically Backed Ingredients

BioCity’s ETA-Selective Antagonist SC0062 Granted Breakthrough Therapy Designation in China for Diabetic Kidney Disease with Albuminuria

Second BTD Recognition Highlights Compound's Potential as Next-Generation Broad-Spectrum Renal TherapySHANGHAI, June 25, 2025 /PRNewswire/ -- BioCity Biopharma ("BioCity") announced today that the Center for...

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26

Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T. 
Company to host Investor Webcast on Thursday, June 26, 2025, at 8:30 am E.T.

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases | DelveInsight

The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in...

Blue Earth Therapeutics: SNMMI Presentation of Results from Lutetium (177Lu) rhPSMA-10.1 Injection Phase 1 Clinical Trial

−  Results show delivery of high radiation doses to tumours compared with normal organs.−  Observed normal organ absorbed dosimetry results may allow administration of...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsReceptor

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers